Recce Pharmaceuticals has received approval for a Phase III trial of RECCE 327 (R327G) in Indonesia for diabetic foot infections. The study aims to enroll 300 patients, with results expected by the end of 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing